ArticleWorld journal of gastroenterology2006
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma.
Article in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 102 citations in OpenAlex.
- Inflammation in MASLD progression and cancer.JHEP reports : innovation in hepatology · 2025Review
- Review
- Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases.Biomedicines · 2024Review
- Targeting hypoxia signaling pathways in angiogenesis.Frontiers in physiology · 2024Review
- Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development.Development & reproduction · 2023Article
- Identification of Anoikis-Related Subgroups and Prognosis Model in Liver Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?International journal of molecular sciences · 2022Review
- Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows.World journal of gastrointestinal oncology · 2022Review
- Review
- The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer.Frontiers in immunology · 2021Review
- Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.Cellular & molecular immunology · 2021Review
- Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma.Frontiers in immunology · 2021Review
- Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges.Frontiers in cell and developmental biology · 2021Review
- Antitumour dendritic cell vaccination in a priming and boosting approach.Nature reviews. Drug discovery · 2020Review
- Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.Experimental & molecular medicine · 2020Review
- Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma.International journal of molecular sciences · 2020Review
- Advances in Molecular Mechanisms for Traditional Chinese Medicine Actions in Regulating Tumor Immune Responses.Frontiers in pharmacology · 2020Review
- The future is now: beyond first line systemic therapy in hepatocellular carcinoma.Translational cancer research · 2019Review
- IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma.Cancer management and research · 2019Article
- Gr1Journal of leukocyte biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo analyze the phenotype and function of dendritic cells (DC) from patients with hepatocellular carcinoma (HCC) in order to understand their role in this disease.
methodsMyeloid dendritic cells were enumerated in peripheral blood of HCC patients. CD80, CD83, CD86 and HLA-DR expression on naive and stimulated myeloid dendritic cells from peripheral blood were analyzed. Myeloid dendritic cells were isolated from peripheral blood and their function was tested. Phagocytosis was analyzed using FITC-dextran beads, peptide specific stimulation, the capacity to stimulate allogeneic T cells and secretion of cytokines upon poly dI:dC was tested.
resultsMyeloid dendritic cells were reduced in patients with HCC. No differences in CD80, CD83, CD86 and HLA-DR expression were found on naive and stimulated myeloid dendritic cells from HCC patients and healthy controls. Normal phagocytosis or stimulation of peptide specific T cells was observed in contrast to an impaired allo-stimulatory capacity and a reduced IL-12 secretion.
conclusionImpaired IL-12 production of mDCs in patients could lead to an impaired stimulatory capacity of naive T cells suggesting that IL-12 directed therapies may enhance tumor specific immune responses in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.